Merck’s Mavenclad is being backed by the National Institute for Health and Clinical Excellence as an option for treating highly active multiple sclerosis in adults on the NHS.
News
Sanofi buys rights to Principia’s BTK inhibitor
Sanofi has bought itself rights to Principia BioPharma’s experimental tyrosine kinase (BTK) inhibitor PRN2246, in a deal potentially worth more than $800 million to the latter firm.
AZ books 3 percent sales drop for Q3
AstraZeneca has booked another sales decline for the third quarter but says the impact of generic competition is starting to wane.
BI signs deal with MiNA to develop liver disease drugs
Boehringer Ingelheim has signed a second deal focused on the development of RNA therapeutics for liver diseases.
NICE brings on board Sigma to boost med tech uptake
The National Institute for Health and Care Excellence is linking with user experience agency Sigma to develop a new system to improve the identification of medical technologies for use in the NHS.
GSK confirms departure of R&D chief
Ending days of speculation GlaxoSmithKline has now confirmed the departure of its current R&D chief Patrick Vallance. The drugs giant has also presented new data for lupus drug Benlysta.
EFPIA urges co-operation to protect patients post Brexit
Nearly half (45 percent) of members of the European Federation of Pharmaceutical Industries and Associations members are expecting trade delays if the UK and Europe fail to reach a deal for Brexit.
Novartis ties with Royal Marsden to boost cancer care
Cancer patients living in North West and South West London are to benefit from a new Joint Working Project between Novartis and the Royal Marsden Partners Cancer Vanguard that aims to improve quality of care in the region by expanding the role of oncology pharmacists.
FDA OKs Roche’s Zelboraf for rare blood disease
US regulators have approved Roche’s Zelboraf (vemurafenib) for patients with a rare blood condition called Erdheim-Chester disease (ECD) carrying a mutation called BRAF V600
NICE turns down Bayer’s Stivarga for liver cancer
Bayer’s Stivarga is not being recommended by NHS treatment cost regulators for certain patients with advanced unresectable hepatocellular carcinoma.
GSK files Nucala for COPD
GlaxoSmithKline is seeking permission to market its asthma biologic mepolizumab for the treatment of eosinophilic chronic obstructive pulmonary disease (COPD) in the US.
Overseas recruitment essential to NHS, say trust chiefs
Any significant cut in the number of overseas staff working in the NHS in the next few years is likely to have a “serious and damaging impact” on services, NHS Providers is warning.
No-deal Brexit could create meds supply chaos, warns report
In the event that the UK fails to reach a deal for Brexit there would be “substantial problems” for the NHS, warns a new analysis by independent think tank The Nuffield Trust.
Bayer files low-dose Xarelto/aspirin combo
Bayer is seeking permission to market in Europe its bloodthinner Xarelto in combination with aspirin to reduce the risk of cardiovascular events in patients with coronary or peripheral artery disease.
Roche’s Alecensa wins wider US approval for lung cancer
Roche group Genentech says its application to expand the use of Alecensa to include first-line treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) has been approved by US regulators.
